MX2021006943A - Anelosomas para suministrar modalidades terapéuticas secretadas. - Google Patents
Anelosomas para suministrar modalidades terapéuticas secretadas.Info
- Publication number
- MX2021006943A MX2021006943A MX2021006943A MX2021006943A MX2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A MX 2021006943 A MX2021006943 A MX 2021006943A
- Authority
- MX
- Mexico
- Prior art keywords
- anellosomes
- therapeutic modalities
- secreted therapeutic
- delivering
- delivering secreted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778866P | 2018-12-12 | 2018-12-12 | |
| US201862778869P | 2018-12-12 | 2018-12-12 | |
| PCT/US2019/065919 WO2020123773A2 (en) | 2018-12-12 | 2019-12-12 | Anellosomes for delivering secreted therapeutic modalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006943A true MX2021006943A (es) | 2021-11-17 |
Family
ID=69160343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006943A MX2021006943A (es) | 2018-12-12 | 2019-12-12 | Anelosomas para suministrar modalidades terapéuticas secretadas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230048858A1 (https=) |
| EP (1) | EP3894568A2 (https=) |
| JP (2) | JP2022512395A (https=) |
| KR (1) | KR20210131309A (https=) |
| CN (1) | CN113631717A (https=) |
| AU (1) | AU2019396520A1 (https=) |
| BR (1) | BR112021009379A2 (https=) |
| CA (1) | CA3119531A1 (https=) |
| IL (1) | IL283778A (https=) |
| MX (1) | MX2021006943A (https=) |
| WO (1) | WO2020123773A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11624061B2 (en) | 2017-04-28 | 2023-04-11 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| BR112020005803A2 (pt) | 2017-09-25 | 2020-12-01 | Agrospheres, Inc. | composições e métodos para produção e administração moduláveis de produtos biológicos |
| BR112021011124A2 (pt) * | 2018-12-12 | 2022-03-15 | Flagship Pioneering Innovations V Inc | Anelossomos e métodos de uso |
| JP2022513459A (ja) * | 2018-12-12 | 2022-02-08 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | タンパク質代替治療モダリティを送達するためのアネロソーム |
| JP2023530451A (ja) * | 2020-06-17 | 2023-07-18 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | アネロウイルスを同定し及び特徴付ける方法並びにその使用 |
| JP2023548838A (ja) * | 2020-10-29 | 2023-11-21 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | ニワトリ貧血ウイルス（ｃａｖ）に基づくベクター |
| KR20230146560A (ko) * | 2021-02-08 | 2023-10-19 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 하이브리드 aav-아넬로벡터 |
| WO2022241013A1 (en) * | 2021-05-12 | 2022-11-17 | Flagship Pioneering Innovations V, Inc. | Anellovectors and methods of use |
| CN118284411A (zh) * | 2021-10-12 | 2024-07-02 | 旗舰先锋创新V股份有限公司 | 新颖的指环载体组合物和方法 |
| EP4415695A4 (en) * | 2021-10-12 | 2025-11-26 | Flagship Pioneering Innovations V Inc | NEW ANELLOVECTOR COMPOSITIONS AND METHODS |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| TW202529819A (zh) | 2023-10-13 | 2025-08-01 | 美商旗艦先鋒創新公司 | 組織特異性指環載體(anellovector)遞送 |
| CN117695410B (zh) * | 2024-02-06 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | CRISPR/Cas9纳米抗菌剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395472B1 (en) * | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
| AU2014361781B2 (en) * | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
| CN108291216B (zh) * | 2015-09-24 | 2022-09-16 | 宾夕法尼亚州大学信托人 | 用于治疗补体介导的疾病的组合物和方法 |
| IL271275B1 (en) * | 2017-06-13 | 2026-04-01 | Flagship Pioneering Innovations V Inc | Preparations containing croons and their uses |
| BR112020007405A2 (pt) * | 2017-10-18 | 2020-12-08 | Regenxbio Inc. | Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos |
-
2019
- 2019-12-12 KR KR1020217021775A patent/KR20210131309A/ko active Pending
- 2019-12-12 CN CN201980091251.6A patent/CN113631717A/zh active Pending
- 2019-12-12 AU AU2019396520A patent/AU2019396520A1/en active Pending
- 2019-12-12 MX MX2021006943A patent/MX2021006943A/es unknown
- 2019-12-12 EP EP19836323.6A patent/EP3894568A2/en active Pending
- 2019-12-12 US US17/413,207 patent/US20230048858A1/en not_active Abandoned
- 2019-12-12 CA CA3119531A patent/CA3119531A1/en active Pending
- 2019-12-12 JP JP2021533524A patent/JP2022512395A/ja active Pending
- 2019-12-12 WO PCT/US2019/065919 patent/WO2020123773A2/en not_active Ceased
- 2019-12-12 BR BR112021009379-6A patent/BR112021009379A2/pt unknown
-
2021
- 2021-06-07 IL IL283778A patent/IL283778A/en unknown
-
2024
- 2024-05-22 JP JP2024083619A patent/JP2024100936A/ja active Pending
-
2025
- 2025-06-17 US US19/240,368 patent/US20260009050A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020123773A9 (en) | 2020-08-27 |
| WO2020123773A2 (en) | 2020-06-18 |
| EP3894568A2 (en) | 2021-10-20 |
| JP2022512395A (ja) | 2022-02-03 |
| KR20210131309A (ko) | 2021-11-02 |
| BR112021009379A2 (pt) | 2021-08-17 |
| CN113631717A (zh) | 2021-11-09 |
| IL283778A (en) | 2021-07-29 |
| US20230048858A1 (en) | 2023-02-16 |
| JP2024100936A (ja) | 2024-07-26 |
| WO2020123773A3 (en) | 2020-07-23 |
| CA3119531A1 (en) | 2020-06-18 |
| AU2019396520A1 (en) | 2021-05-27 |
| US20260009050A1 (en) | 2026-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006943A (es) | Anelosomas para suministrar modalidades terapéuticas secretadas. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| MX2020002666A (es) | Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato. | |
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| BR112021024754A2 (pt) | Vesículas extracelulares microbianas secretadas | |
| PE20200617A1 (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39 | |
| MX2018015252A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
| MX369041B (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| MX2019015018A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| BR112019004785A2 (pt) | variantes de alfa-glicosidase ácida e usos das mesmas | |
| DK3740504T3 (da) | CD70 kombinationsterapi | |
| BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
| MX2018003700A (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos. | |
| BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
| EP3860585A4 (en) | Therapeutic compositions | |
| CL2021002331A1 (es) | Formulaciones de anticuerpo anti-il-36r | |
| EP3735463A4 (en) | Cytotoxicity-inducing therapeutic agent | |
| AR109376A1 (es) | FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA | |
| UY35463A (es) | Formulaciones de polipéptido fc-factor ix. | |
| MX2021006941A (es) | Anelosomas para suministrar modalidades terapéuticas intracelulares. | |
| BR112017002090A2 (pt) | formulação de fator viii | |
| EP3755678A4 (en) | FORMULATION OF A BIOSTIMULANT | |
| EP3864058A4 (en) | PHOTOCURABLE COMPOSITION | |
| EP3755376A4 (en) | FORMULATIONS CONTAINING PROTEASIS AFFECTING THE MUCINE | |
| DK3911298T3 (da) | Formuleringer |